-
Study: Jevtana combined with Novantrone reduced death risk in prostate cancer patients
BRIDGEWATER, N.J. Data published in the latest issue of medical journal The Lancet showed that a recently approved drug reduced the risk of death in men with a certain form of prostate cancer by more than a quarter.
-
Centocor Ortho Biotech seeks expanded approval for Simponi
HORSHAM, Pa. The biotech division of Johnson & Johnson is hoping to expand the use of a treatment for autoimmune disorders.
Centocor Ortho Biotech said it had filed an application with the Food and Drug Administration to get approval for Simponi (golimumab) to stop the progression of structural damage, induce major clinical response, maintain reductions in signs and symptoms, and improve physical function in the treatment of rheumatoid arthritis.